Performance · Recovery · Longevity

Shopping Cart (0)

Catalogue

Shop

Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).

Research peptides & wellness compounds

Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.

Retatrutide 30mg (UPRET)

Category:
Weight Loss / Metabolic / Longevity
SKU:
TRW-RETA
Price:
R 2050.00
{{variant.name}}:
{{opt.name}}
{{opt.value ? '' : opt.name}}
{{opt.value ? '' : opt.name}}
Description

TEST RUN WELLNESS UPRET 30 | Retatrutide 30mg Self-Mix Vial

 

UPRET 30 (Retatrutide 30mg) – Advanced triple agonist peptide for elite appetite control, glucose regulation, and fat loss support. 30mg multi-dose vial kit with bacteriostatic water. Next-generation triple agonist series.

 

Product Overview

UPRET 30 is a Retatrutide 30mg self-mix vial. Retatrutide (LY3437943) is a first-in-class unimolecular triple agonist that simultaneously activates three G-protein–coupled receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCG (glucagon) receptors.

 

By integrating the appetite-suppressive effects of GLP-1, the insulin-sensitising properties of GIP, and the energy expenditure-enhancing actions of glucagon, retatrutide is designed to maximise weight loss and metabolic improvement through complementary hormonal pathways.

 

Cryo-EM structural studies reveal a combination of conserved peptide–receptor interactions and receptor-specific conformations, particularly in ECL1, that enables retatrutide to execute agonism at multiple receptors.

 

How Retatrutide Works: Triple GIP/GLP-1/Glucagon

Pathway Agonist

Retatrutide's triple mechanism represents a step beyond single and dual incretin agonists. GLP-1 enhances insulin secretion in a glucose-dependent manner, reduces glucagon secretion, delays gastric emptying, and suppresses appetite.

 

GIP complements GLP-1 by improving fat metabolism and insulin sensitivity. Glucagon, while traditionally recognized as a counterregulatory hormone that raises blood glucose, has potent catabolic effects — it stimulates adipose lipolysis, reduces food intake, slows gastric emptying, and increases energy expenditure.

 

By incorporating glucagon receptor activation into GLP-1/GIP-based therapy, retatrutide aims to counteract the metabolic adaptation that limits weight loss over time. Simultaneously, the incretin-mimetic action of GLP-1 and GIP signaling balances the potential adverse glycemic effects of glucagon.

 

Body Recomposition Benefits

Clinical evidence demonstrates that retatrutide induces favourable body composition changes. In a Phase 2 body-composition substudy involving people with type 2 diabetes, a pooled 8 mg retatrutide regimens reduced body weight by approximately 16.8 kg over 36 weeks, compared with 2.1 kg with placebo and 0.8 kg with dulaglutide.

 

Retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide, with the proportion of lean mass loss to weight loss similar to other obesity treatments. Importantly, the retatrutide DXA substudy showed smaller absolute and proportional reductions in lean mass in lower-dose groups than in higher-dose groups, with lean mass accounting for approximately 16% and 30% of weight loss in the 0.5 mg and 4 mg groups, respectively.

 

Preclinical data in female mice demonstrated that muscle mass was preserved with retatrutide despite enhanced weight loss versus pair-fed controls, without changes in strength or ATP production.

 

Titration Protocol

Retatrutide is administered as a once-weekly subcutaneous injection. Clinical trials used gradual dose escalation to minimise gastrointestinal side effects, with increases every 4 weeks.

 

The most common starting dose was 2 mg weekly, escalating every four weeks to maintenance doses between 4 mg and 12 mg weekly. A standard escalation schedule is as follows:

· Weeks 1–4: 2 mg once weekly — starting dose, allows digestive adaptation
· Weeks 5–8: 4 mg once weekly — first escalation
· Weeks 9–12: 8 mg once weekly — second escalation
· Week 13+: Target dose (8 mg, 9 mg, or 12 mg) — maintenance.

 

In the Phase 2 trial, dose escalation was completed by week 12 for groups assigned to doses of 4 mg or greater. The 12 mg dose group followed a schedule of 2 mg for weeks 1–4, then escalated at 4-week intervals up to 12 mg. Dose escalation should only proceed if the current dose is well tolerated. There is no FDA-approved dose of retatrutide; all dosing regimens remain experimental.

 

Combination Therapy

Combination therapies represent a promising strategy to enhance the efficacy and tolerability of incretin-based treatments. Dual agonists such as tirzepatide (GLP-1/GIP) have demonstrated superior weight loss and glycemic control compared to GLP-1 receptor agonists alone, likely due to complementary mechanisms involving both incretin pathways.

 

Triple agonists targeting GLP-1, GIP, and glucagon receptors, such as retatrutide, have shown even greater weight loss effects in early-phase trials.

Preclinical research has explored retatrutide combined with cagrilintide, an amylin and calcitonin receptor agonist. In diet-induced obese rats, the combination of retatrutide and cagrilintide — simultaneously activating five key metabolic hormone receptors — demonstrated enhanced weight loss and metabolic outcomes compared to monotherapies.

 

Other potential combinations include GLP-1 receptor agonists with SGLT-2 inhibitors, amylin analogues, or central nervous system appetite modulators. GLP-3R peptide stacking combines retatrutide with secondary peptides such as tesamorelin or BPC-157 to support weight loss, muscle preservation, or inflammation control. All combination approaches should be pursued under professional medical supervision.

 

Clinical Trial Record

Retatrutide has demonstrated unprecedented efficacy across Phase 2 and Phase 3 clinical trials:

· Phase 2 obesity trial: Mean weight loss of up to 24.2% over 48 weeks at the 12 mg dose in adults with obesity. Weight loss was 18% at 24 weeks at the highest dose, with 26% of participants achieving 30% or greater weight loss at 48 weeks.


· Phase 3 TRIUMPH-1: Mean body weight reductions of −17.6% (4 mg), −23.7% (9 mg), and −25.0% (12 mg) versus −3.9% for placebo at 80 weeks.


· Phase 3 TRIUMPH-2 (T2D): Participants lost an average of 12.7% (4 mg), 19.1% (9 mg), and 20.8% (12 mg) at 80 weeks, alongside A1C reductions of up to 1.6%.


· Phase 3 TRIUMPH-3 (severe obesity + CVD): Weight loss up to an average of 22.6% at 80 weeks, with significant reductions in triglycerides, non-HDL cholesterol, systolic blood pressure, and waist circumference.


· Phase 3 TRANSCEND-T2D-1: Mean body weight changes of −11.5% (4 mg), −13.9% (9 mg), and −15.3% (12 mg) versus −2.6% for placebo.

 

Technical Specifications

· Product Name: UPRET 30
· Peptide: Retatrutide (LY3437943)
· Concentration: 30mg per vial
· Form: Self-mix multi-dose vial
· Reconstitution: Requires bacteriostatic water for reconstitution
· Administration: Once-weekly subcutaneous injection
· Supplier: Test Run Wellness (Wellness.testrun)

 

⚕️ Important Medical Notice

Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. UPRET 30 is intended for use under professional medical supervision. 

Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.